The Door Opens Before the Science Settles
A consumer walks from the gray-market world of experimental peptides toward the cleaner, more familiar setting of a licensed pharmacy. That shift is the signal. The FDA has moved an interim peptide-compounding policy into White House review, creating the possibility that some products could become easier to obtain from pharmacies even though they remain unapproved as drugs. The visual shows access moving faster than certainty: the pathway is becoming more legitimate and more convenient before the underlying questions about safety and effectiveness have been resolved. SSC_Daily_Visual_Signal_Product…
Read the full story: The Peptide Door Is Moving From Discussion to Policy